toripalimab
Shanghai Junshi Bioscience,coherus
['toripalimab', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'choice-01']
avm: choice-01 toripalimab (pd1) vs. placebo in combination chemotherapy in nsclc adds to multiple trials showing known benefit of icis
os hr 0.73
non-squamous subgroup w/ better outcomes os hr 0.50, median os 27.8 vs 15.9 mo
#lcsm #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.